These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 22717926)

  • 21. Rosuvastatin and progression of atherosclerosis.
    Nicholls SJ
    Expert Rev Cardiovasc Ther; 2008 Aug; 6(7):925-33. PubMed ID: 18666843
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Noninvasive detection of subclinical coronary atherosclerosis coupled with assessment of changes in plaque characteristics using novel invasive imaging modalities: the Integrated Biomarker and Imaging Study (IBIS).
    Van Mieghem CA; McFadden EP; de Feyter PJ; Bruining N; Schaar JA; Mollet NR; Cademartiri F; Goedhart D; de Winter S; Granillo GR; Valgimigli M; Mastik F; van der Steen AF; van der Giessen WJ; Sianos G; Backx B; Morel MA; van Es GA; Zalewski A; Serruys PW
    J Am Coll Cardiol; 2006 Mar; 47(6):1134-42. PubMed ID: 16545642
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Letter by Sutton et al regarding article, "Effect of rosuvastatin therapy on coronary artery stenoses assessed by quantitative coronary angiography: a study to evaluate the effect of rosuvastatin on intravascular ultrasound-derived coronary atheroma burden".
    Sutton BS; Blumenthal RS; Kapur NK
    Circulation; 2008 Nov; 118(22):e707; author reply e708-9. PubMed ID: 19029474
    [No Abstract]   [Full Text] [Related]  

  • 24. Letter by Kaneda regarding article, "Effect of rosuvastatin therapy on coronary artery stenoses assessed by quantitative coronary angiography: a study to evaluate the effect of rosuvastatin on intravascular ultrasound-derived coronary atheroma burden".
    Kaneda H
    Circulation; 2008 Nov; 118(22):e706; author reply e708-9. PubMed ID: 19029473
    [No Abstract]   [Full Text] [Related]  

  • 25. Combination therapy of eicosapentaenoic acid and pitavastatin for coronary plaque regression evaluated by integrated backscatter intravascular ultrasonography (CHERRY study)-rationale and design.
    Watanabe T; Miyamoto T; Miyasita T; Shishido T; Arimoto T; Takahashi H; Nishiyama S; Hirono O; Matsui M; Sugawara S; Ikeno E; Miyawaki H; Akira F; Kubota I
    J Cardiol; 2014 Sep; 64(3):236-9. PubMed ID: 24503140
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lipid-altering efficacy of ezetimibe/simvastatin 10/20 mg compared with rosuvastatin 10 mg in high-risk hypercholesterolaemic patients inadequately controlled with prior statin monotherapy - The IN-CROSS study.
    Farnier M; Averna M; Missault L; Vaverkova H; Viigimaa M; Massaad R; Vandormael K; Johnson-Levonas AO; Brudi P
    Int J Clin Pract; 2009 Apr; 63(4):547-59. PubMed ID: 19222610
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Rationale and design of the EPISTEME trial: efficacy of post-stroke intensive rosuvastatin treatment for aortogenic embolic stroke.
    Ueno Y; Yamashiro K; Tanaka Y; Watanabe M; Shimada Y; Kuroki T; Miyamoto N; Daimon M; Tanaka R; Miyauchi K; Daida H; Hattori N; Urabe T
    Cardiovasc Drugs Ther; 2014 Feb; 28(1):79-85. PubMed ID: 24072337
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rapid immunomodulation by rosuvastatin in patients with acute coronary syndrome.
    Link A; Ayadhi T; Böhm M; Nickenig G
    Eur Heart J; 2006 Dec; 27(24):2945-55. PubMed ID: 17012299
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rosuvastatin 5 and 10 mg/d: a pilot study of the effects in hypercholesterolemic adults unable to tolerate other statins and reach LDL cholesterol goals with nonstatin lipid-lowering therapies.
    Glueck CJ; Aregawi D; Agloria M; Khalil Q; Winiarska M; Munjal J; Gogineni S; Wang P
    Clin Ther; 2006 Jun; 28(6):933-42. PubMed ID: 16860175
    [TBL] [Abstract][Full Text] [Related]  

  • 30. High HbA1c levels correlate with reduced plaque regression during statin treatment in patients with stable coronary artery disease: results of the coronary atherosclerosis study measuring effects of rosuvastatin using intravascular ultrasound in Japanese subjects (COSMOS).
    Daida H; Takayama T; Hiro T; Yamagishi M; Hirayama A; Saito S; Yamaguchi T; Matsuzaki M;
    Cardiovasc Diabetol; 2012 Jul; 11():87. PubMed ID: 22831708
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Achieving LDL cholesterol, non-HDL cholesterol, and apolipoprotein B target levels in high-risk patients: Measuring Effective Reductions in Cholesterol Using Rosuvastatin therapY (MERCURY) II.
    Ballantyne CM; Bertolami M; Hernandez Garcia HR; Nul D; Stein EA; Theroux P; Weiss R; Cain VA; Raichlen JS
    Am Heart J; 2006 May; 151(5):975.e1-9. PubMed ID: 16644314
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rosuvastatin may reduce the incidence of cardiovascular events in patients with acute coronary syndromes receiving percutaneous coronary intervention by suppressing miR-155/SHIP-1 signaling pathway.
    Xie W; Li P; Wang Z; Chen J; Lin Z; Liang X; Mo Y
    Cardiovasc Ther; 2014 Dec; 32(6):276-82. PubMed ID: 25319951
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and safety of rosuvastatin and atorvastatin in patients with hypercholesterolemia and a high risk of coronary heart disease: a randomized, controlled trial.
    Schwartz GG; Bolognese MA; Tremblay BP; Caplan R; Hutchinson H; Raza A; Cressman M
    Am Heart J; 2004 Jul; 148(1):e4. PubMed ID: 15215813
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of rosuvastatin on coronary atheroma in stable coronary artery disease: multicenter coronary atherosclerosis study measuring effects of rosuvastatin using intravascular ultrasound in Japanese subjects (COSMOS).
    Takayama T; Hiro T; Yamagishi M; Daida H; Hirayama A; Saito S; Yamaguchi T; Matsuzaki M;
    Circ J; 2009 Nov; 73(11):2110-7. PubMed ID: 19801853
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The beneficial effect of high loading dose of rosuvastatin before percutaneous coronary intervention in patients with acute coronary syndrome.
    Yun KH; Jeong MH; Oh SK; Rhee SJ; Park EM; Lee EM; Yoo NJ; Kim NH; Ahn YK; Jeong JW
    Int J Cardiol; 2009 Nov; 137(3):246-51. PubMed ID: 18706705
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Rosuvastatin in the management of hyperlipidemia.
    Cheng JW
    Clin Ther; 2004 Sep; 26(9):1368-87. PubMed ID: 15531000
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In vivo characterization of coronary plaques: novel findings from comparing greyscale and virtual histology intravascular ultrasound and near-infrared spectroscopy.
    Pu J; Mintz GS; Brilakis ES; Banerjee S; Abdel-Karim AR; Maini B; Biro S; Lee JB; Stone GW; Weisz G; Maehara A
    Eur Heart J; 2012 Feb; 33(3):372-83. PubMed ID: 22019821
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Rosuvastatin: a review of its use in the prevention of cardiovascular disease in apparently healthy women or men with normal LDL-C levels and elevated hsCRP levels.
    Carter NJ
    Am J Cardiovasc Drugs; 2010; 10(6):383-400. PubMed ID: 21090831
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Relationship between tissue type plasminogen activator and coronary vulnerable plaque in patients with acute coronary syndrome: virtual histological study.
    Wang HB; Kang WQ; Song DL; Wang X; Ren GR; Teng JL; Ge ZM
    Chin Med J (Engl); 2008 Mar; 121(6):540-3. PubMed ID: 18364143
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Haptoglobin polymorphism in relation to coronary plaque characteristics on radiofrequency intravascular ultrasound and near-infrared spectroscopy in patients with coronary artery disease.
    Buljubasic N; Oemrawsingh RM; Smeets MB; Cheng JM; Regar E; van Geuns RJ; Serruys PW; Boersma E; Akkerhuis KM; Kardys I; Arslan F
    Int J Cardiol; 2016 Oct; 221():682-7. PubMed ID: 27423090
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.